New drug cocktail shows promise for tough head and neck cancer
NCT ID NCT05459129
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tested combinations of immunotherapy drugs (atezolizumab and tiragolumab) plus chemotherapy (carboplatin and paclitaxel) in 12 people with advanced head and neck cancer that had not been treated before. The goal was to see if these combinations could completely eliminate the tumor before surgery. The study is complete, but results are still being analyzed to determine how well the treatments worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab, Tiragolumab, Carboplatin, Paclitaxel
What this could lead to
If successful, this could point toward more effective treatment combinations for advanced head and neck cancer.
What could go wrong
This is an early-phase trial with only 12 participants, so results are preliminary. The drug combinations may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
City of Hope
Duarte, California, 91010, United States
-
Hadassah University Hospital - Ein Kerem
Jerusaelm, 9112001, Israel
-
Severance Hospital - Yonsei Cancer Center
Seoul, 03722, South Korea
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States